878 related articles for article (PubMed ID: 32872332)
41. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Caocci G; La Nasa G
Ann Hematol; 2020 Jul; 99(7):1675-1676. PubMed ID: 32405693
[No Abstract] [Full Text] [Related]
42. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.
Choudhury R; Barrett CD; Moore HB; Moore EE; McIntyre RC; Moore PK; Talmor DS; Nydam TL; Yaffe MB
World J Emerg Surg; 2020 Apr; 15(1):29. PubMed ID: 32312290
[TBL] [Abstract][Full Text] [Related]
43. A novel cell-based assay for dynamically detecting neutrophil extracellular traps-induced lung epithelial injuries.
Lv D; Xu Y; Cheng H; Ke Y; Zhang X; Ying K
Exp Cell Res; 2020 Sep; 394(2):112101. PubMed ID: 32474064
[TBL] [Abstract][Full Text] [Related]
44. [Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019].
Zhang T; Sun LX; Feng RE
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jun; 43(6):496-502. PubMed ID: 32241072
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia.
Correale P; Caracciolo M; Bilotta F; Conte M; Cuzzola M; Falcone C; Mangano C; Falzea AC; Iuliano E; Morabito A; Foti G; Armentano A; Caraglia M; De Lorenzo A; Sitkovsky M; Macheda S
PLoS One; 2020; 15(10):e0239692. PubMed ID: 33031409
[TBL] [Abstract][Full Text] [Related]
46. Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients.
Jouan Y; Guillon A; Gonzalez L; Perez Y; Boisseau C; Ehrmann S; Ferreira M; Daix T; Jeannet R; François B; Dequin PF; Si-Tahar M; Baranek T; Paget C
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32886755
[TBL] [Abstract][Full Text] [Related]
47. [Therapy of coronavirus disease 2019 induced acute respiratory distress syndrome is different from traditional acute respiratory distress syndrome].
Pan C; Xie JF; Qiu HB; Yang Y
Zhonghua Shao Shang Za Zhi; 2020 May; 36(5):330-333. PubMed ID: 32456368
[TBL] [Abstract][Full Text] [Related]
48. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study.
Russo V; Di Maio M; Attena E; Silverio A; Scudiero F; Celentani D; Lodigiani C; Di Micco P
Pharmacol Res; 2020 Sep; 159():104965. PubMed ID: 32474087
[TBL] [Abstract][Full Text] [Related]
49. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
Castelli V; Cimini A; Ferri C
Front Immunol; 2020; 11():2132. PubMed ID: 32983172
[TBL] [Abstract][Full Text] [Related]
50. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
Loganathan S; Athalye SN; Joshi SR
Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
[TBL] [Abstract][Full Text] [Related]
51. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
Qin H; Zhao A
Protein Cell; 2020 Oct; 11(10):707-722. PubMed ID: 32519302
[TBL] [Abstract][Full Text] [Related]
52. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
53. Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury.
Rieder SA; Nagarkatti P; Nagarkatti M
Br J Pharmacol; 2012 Nov; 167(6):1244-58. PubMed ID: 22646800
[TBL] [Abstract][Full Text] [Related]
54. Transcription Factor Nrf2 as a Potential Therapeutic Target for Prevention of Cytokine Storm in COVID-19 Patients.
Zinovkin RA; Grebenchikov OA
Biochemistry (Mosc); 2020 Jul; 85(7):833-837. PubMed ID: 33040727
[TBL] [Abstract][Full Text] [Related]
55. Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets.
Karmouty-Quintana H; Thandavarayan RA; Keller SP; Sahay S; Pandit LM; Akkanti B
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138181
[TBL] [Abstract][Full Text] [Related]
56. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.
Orienti I; Gentilomi GA; Farruggia G
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471278
[TBL] [Abstract][Full Text] [Related]
57. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications.
Pelaia C; Tinello C; Vatrella A; De Sarro G; Pelaia G
Ther Adv Respir Dis; 2020; 14():1753466620933508. PubMed ID: 32539627
[TBL] [Abstract][Full Text] [Related]
58. Resveratrol attenuates staphylococcal enterotoxin B-activated immune cell metabolism
Alghetaa H; Mohammed A; Singh N; Wilson K; Cai G; Putluri N; Nagarkatti M; Nagarkatti P
Front Pharmacol; 2023; 14():1106733. PubMed ID: 36909201
[TBL] [Abstract][Full Text] [Related]
59. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.
Qu W; Wang Z; Hare JM; Bu G; Mallea JM; Pascual JM; Caplan AI; Kurtzberg J; Zubair AC; Kubrova E; Engelberg-Cook E; Nayfeh T; Shah VP; Hill JC; Wolf ME; Prokop LJ; Murad MH; Sanfilippo FP
Stem Cells Transl Med; 2020 Sep; 9(9):1007-1022. PubMed ID: 32472653
[TBL] [Abstract][Full Text] [Related]
60. Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy.
Cafarotti S
J Thorac Oncol; 2020 Jul; 15(7):e101-e103. PubMed ID: 32353597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
